目的 探讨慈丹胶囊联合厄洛替尼治疗晚期非小细胞肺癌的临床疗效。方法 收集2014年3月-2016年3月在保定市第一医院治疗的晚期非小细胞肺癌患者94例，随机分为对照组（47例）和治疗组（47例）。对照组患者口服盐酸厄洛替尼片，150 mg/次，1次/d，直到疾病进展或出现不能耐受的毒性反应。治疗组患者在对照组的基础上口服慈丹胶囊，1.35 g/次，4次/d。两组均经过2个月治疗。评价两组患者临床疗效，同时比较治疗前后两组患者肿瘤标志物水平、血清学指标、QLQ-C30评分、疾病进展时间和平均生存时间。结果 治疗后，对照组客观缓解率为27.66%，临床获益率为74.47%，均分别低于治疗组的48.94%、91.49%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组癌胚抗原（CEA）、CA153、CA242水平均显著降低（P<0.05）；且治疗组比对照组降低更显著（P<0.05）。治疗后，两组血清血管内皮生长因子（VEGF）、基质金属蛋白酶-2（MMP-2）、可溶性细胞黏附因子-1（sICAM-1）和S100钙结合蛋白A4（S100A4）水平均明显降低（P<0.05）；且治疗组降低的更明显（P<0.05）。治疗后，两组躯体、认知、情绪、角色和社会功能等QLQ-C30功能领域评分均显著升高（P<0.05）；且治疗组比对照组升高更显著（P<0.05）。治疗后，治疗组患者疾病进展时间和平均生存时间均明显优于对照组患者，两组比较差异具有统计学意义（P<0.05）。结论 慈丹胶囊联合厄洛替尼治疗晚期非小细胞肺癌可有效降低血清肿瘤标志物水平，延长生存时间，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Cidan Capsules combined with erlotinib in treatment of advanced non-small cell lung cancer. Methods Patients (94 cases) with advanced non-small cell lung cancer in Baoding No.1 Hospital from March 2014 to March 2016 were randomly divided into control (47 cases) and treatment (47 cases) groups. Patients in the control group were po administered with Erlotinib Hydrochloride Tablets until the disease progress or the emergence of intolerable toxicity, 150 mg/time, once daily. Patients in the treatment group were po administered with Cidan Capsules on the basis of the control group, 1.35 g/time, four times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the tumor markers levels, serological indexes, QLQ-C30s score, the time of disease progression and average survival in two groups before and after treatment were compared. Results After treatment, objective remission rate and disease control rate in the control group were 27.66% and 74.47%, which were significantly lower than 48.94% and 91.49% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the CEA, CA153 and CA242 levels in two groups were significantly decreased (P<0.05). And these indexes levels in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, the VEGF, MMP-2, sICAM-1 and S100A4 levels in two groups were significantly decreased (P<0.05). And these indexes levels in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, the QLQ-C30 scores of body, cognition, emotion, role and social function in the treatment group were obviously increased (P<0.05). And these scores in the treatment group were obviously higher than that in the control group (P<0.05). After treatment, the time of disease progression and average survival in the treatment group were obviously better than that in the control group, with significant difference between two groups (P<0.05). Conclusion Cidan Capsules combined with erlotinib can effectively reduce the serum tumor markers level and prolong the survival time in treatment of advanced non-small cell lung cancer, which has a certain clinical application value.